Back to Journals » Therapeutics and Clinical Risk Management » Volume 4 » Issue 2

Review of the combined contraceptive vaginal ring, NuvaRing®

Authors Roumen FJME

Published 11 April 2008 Volume 2008:4(2) Pages 441—451

DOI https://doi.org/10.2147/TCRM.S1964

Frans JME Roumen

Department of Obstetrics and Gynecology, Atrium Medical Centre Parkstad, Heerlen, The Netherlands

Abstract: The purpose of this review was to test contraceptive efficacy, cycle control, tolerability, and acceptability as found in the non-comparative studies with NuvaRing® by those found in the randomized trials comparing NuvaRing and combined oral contraceptives (COCs). All large non-comparative studies and all relevant randomized controlled trials (RCTs) between NuvaRing and a COC up to and including December 2006 were analyzed. Two large multi-center registration studies, 1 large daily clinical practice study, and 6 RCTs comparing NuvaRing and a COC were identified. The findings in the non-comparative studies were confirmed in the RCTs. Contraceptive efficacy was high showing no significant differences in comparison with the COC; cycle control was good and consistently better than that of the COC; compliance was high and comparable with that of the pill; the incidence of adverse events such as breast tenderness, headache, and nausea was low, but not lower than with the COC despite a halving of the systemic exposure to ethinyl estradiol (EE) with NuvaRing compared with a 30-µg EE-containing COC; the incidence of local and ring-related events was low but higher than with the COC, leading to higher discontinuation rates among NuvaRing users; acceptability was high and comparable between both contraceptives, resulting in a global improvement of sexual function with both methods. After study completion, women using NuvaRing were more likely to continue with their method than women using a COC. The good results with respect to contraceptive efficacy, cycle control, tolerability, and acceptability as achieved with NuvaRing in the large non-comparative registration studies were confirmed in the RCTs comparing NuvaRing with different COCs.

Keywords: acceptability, contraceptive efficacy, cycle control, NuvaRing, tolerability, vaginal ring

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF] 

 

Readers of this article also read:

Perioperative FOLFOX4 plus bevacizumab for initially unresectable advanced colorectal cancer (NAVIGATE-CRC-01)

Suenaga M, Fujimoto Y, Matsusaka S, Shinozaki E, Akiyoshi T, Nagayama S, Fukunaga Y, Oya M, Ueno M, Mizunuma N, Yamaguchi T

OncoTargets and Therapy 2015, 8:1111-1118

Published Date: 18 May 2015

Lung function decline in COPD

Tantucci C, Modina D

International Journal of Chronic Obstructive Pulmonary Disease 2012, 7:95-99

Published Date: 9 February 2012

Sulfation of fulvestrant by human liver cytosols and recombinant SULT1A1 and SULT1E1

Edavana VK, Yu X, Dhakal IB, Williams S, Ning B, Cook IT, Caldwell D, Falany CN, Kadlubar S

Pharmacogenomics and Personalized Medicine 2011, 4:137-145

Published Date: 17 November 2011

Tolerability of NGX-4010, a capsaicin 8% patch for peripheral neuropathic pain

Peppin JF, Majors K, Webster LR, Simpson DM, Tobias JK, Vanhove GF

Journal of Pain Research 2011, 4:385-392

Published Date: 14 November 2011

Erratum

Rapidis A, Sarlis N, Lefebvre J-L, et al

Therapeutics and Clinical Risk Management 2008, 4:1381-1381

Published Date: 5 December 2008

Docetaxel in the treatment of squamous cell carcinoma of the head and neck

Alexander Rapidis, Nicholas Sarlis, Jean-Louis Lefebvre, Merrill Kies

Therapeutics and Clinical Risk Management 2008, 4:865-886

Published Date: 10 October 2008

An “acquired” hemoglobin J variant in a sickle cell disease patient

Nawwar Swedan, Kathleen Nicol, Phylis Moder, Samir Kahwash

Therapeutics and Clinical Risk Management 2008, 4:649-652

Published Date: 6 June 2008

A critical analysis of barriers to the clinical implementation of pharmacogenomics

Ross A McKinnon, Michael B Ward, Michael J Sorich

Therapeutics and Clinical Risk Management 2007, 3:751-759

Published Date: 15 November 2007

Editorial Foreword || FREE PAPER ||

Garry M Walsh

Therapeutics and Clinical Risk Management 2007, 3:705-706

Published Date: 15 November 2007